# Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

> **NCT06534320** · PHASE1 · COMPLETED · sponsor: **Chendu DIAO Pharmaceutical Group CO., LTD.** · enrollment: 50 (actual)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** DA-302168S
- **DRUG:** Placebo of DA-302168S
- **DRUG:** DA-302168S
- **DRUG:** Placebo of DA-302168S

## Key facts

- **NCT ID:** NCT06534320
- **Lead sponsor:** Chendu DIAO Pharmaceutical Group CO., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06534320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06534320, "Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06534320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*